Company Directory / Research
PrivateFor profitResearchBoston, Massachusetts, United States
SeLux Diagnostics
SeLux Diagnostics is a developer of a next-generation phenotyping platform that provides personalized antimicrobial therapies to patients.
- Founded
- 2014 12 years ago
- Staff
- 101-250 band, as listed
- Followers
- - on LinkedIn
- Funding
- $220M as listed, USD
Set against six million companies
Size
101-250 people: larger than 85% of companies with a size listed
Age
12 years old.
Reach
Website ranked #8,105,175 in the world for traffic, about 648 visits a month.
What it does
BiotechnologyHealth CareHealth DiagnosticsTherapeutics
What it is known for
biotechnology researchrapid astbroad antimicrobial panelsmicrobiology automationbacterial shape shiftingmedical equipment and supplies manufacturingclinical microbiologygovernmentfaster diagnostic resultsbacterial cell viabilitynext generation phenotypingcomprehensive bug-drug menumic accuracyservicesupdated breakpointspatient care
What its website runs on
Google Search ConsoleGoDaddy DomainsMicrosoft Email ProvidersMicrosoft Exchange OnlineOutlookMicrosoft ExchangeMicrosoft 365Microsoft 365 Apps & ServicesGoDaddy Hosting
Funding, as listed
$220M raised in total
- Rounds10
- LatestSeries d, Apr 2024
- Latest amountUSD 48,000,000
- Investors7, 6 leading
What the source datasets report. We have not watched these rounds ourselves.
Every detail we hold
Everything the source datasets list about SeLux Diagnostics, field by field. Contact details are held but never shown.
The company
- Name
- SeLux Diagnostics
- Type
- For profit
- Status
- Private
- Founded
- 2014
- Founders
- Aleksandar Vacic, Eric Stern
- Industry
- Research
- Categories
- Biotechnology, Health Care, Health Diagnostics, Therapeutics
Where
- City
- Boston
- Region
- Massachusetts
- Country
- United States
- Markets
- Greater Boston Area, East Coast, New England, Northeastern US
Size and reach
- Staff band
- 101-250
- Web traffic rank
- #8,105,175
- Monthly web visits
- 648
- Annual revenue
- $35M
Funding, as listed
- Total
- $220,499,998 USD
- Rounds
- 10
- Latest round
- Series d
- Latest round date
- Apr 2024
- Latest amount
- 48,000,000 USD
- Investors
- 7
- Lead investors
- 6
- Listing status
- private
Classification
- NAICS
- 33911, 334510, 541714
- SIC
- 3824
- Keywords
- 16 listed, shown above
- Technologies
- 9 detected, shown above
About this record
- Sources
- Crunchbase, Apollo
- Last imported
- Sept 2026
Growth, as the source summarises it
SeLux Diagnostics announced that it received an additional $48 million in funding. Additionally, the Selux PBC Separator with Selux AST System received FDA 510(k) clearance for rapid antibiotic susceptibility testing directly from positive blood culture.
Summaries written by the source dataset, not by us, and not checked.
Companies like it
Research in United States.
Rubius TherapeuticsCambridge · 1-10 people
Kemin IndustriesDes Moines · 1001-5000 peopleBBruker Cellular AnalysisEmeryville · 101-250 people
FermilabBatavia · 1001-5000 people · 96k followers
Alladapt ImmunotherapeuticsMenlo Park · 11-50 peopleFrom the company datasets we hold (Crunchbase, LinkedIn and Apollo listings), as listed there; 1,637,054 companies in United States and 5,926,251 in all. We hold no contact details for public display. Correct this, or ask for it to be removed.